Soligenix Enters Into Exclusive Option Agreement With Silk Road Therapeutics For Rights To Topical Pentoxifylline Designed To Treat Behçet's Disease
Soligenix Enters Into Exclusive Option Agreement With Silk Road Therapeutics For Rights To Topical Pentoxifylline Designed To Treat Behçet's Disease
Soligenix 與 Silk Road Therapeutics 簽訂獨家期權協議,以獲得旨在治療白塞氏病的局部用己酮可可鹼的權利
Soligenix Enters into Exclusive Option Agreement With Silk Road Therapeutics For Rights To Topical Pentoxifylline Designed To Treat Behçet's Disease
Soligenix 與 Silk Road Therapeutics 簽訂獨家期權協議,以獲得旨在治療 Beh√βset 病的局部用己酮可可鹼的權利